#Garsorasib
LightNews LightNews
sigtrans-sttt.bsky.social
#Garsorasib, alone or with #Cetuximab, shows strong efficacy, manageable safety, and a favorable response in heavily pretreated #KRASG12C-mutated metastatic #ColorectalCancer, supporting improved precision therapy outcomes.

#OpenAccess in #STTT: doi.org/10.1038/s413...
November 15, 2025 at 11:15 AM
newsen.bsky.social
InxMed's Latest Study in The Lancet Highlights New Hope for Colorectal Cancer Treatment#China#Nanjing#Ifebemtinib#InxMed#Garsorasib
InxMed's Latest Study in The Lancet Highlights New Hope for Colorectal Cancer Treatment
A recent InxMed study published in The Lancet Oncology showcases the promising potential of Ifebemtinib combined with Garsorasib in treating metastatic colorectal cancer with KRAS G12C mutations.
third-news.com
August 28, 2026 at 11:09 AM
laotiantimes.com.web.brid.gy
InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation
NANJING, China, Aug. 28, 2026 /PRNewswire/ — InxMed Co., Ltd (“InxMed”), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective focal adhesion kinase (FAK) inhibitor, in combination with garsorasib (D-1553), a potent KRAS G12C inhibitor, in previously […]
laotiantimes.com
August 29, 2026 at 10:47 AM
l2plabs.bsky.social
InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation
NANJING, China, Aug. 28, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly...
dlvr.it
August 28, 2026 at 11:05 AM
liz-liz-liz.bsky.social
$RVMD It has been priced as the best KRAS inhibitor in town. Wonder it that would change as more data on Garsorasib becomes available.
January 6, 2025 at 6:47 AM
dengyuemedicine.bsky.social
China NMPA Grants Conditional Approval for Garsorasib Tablets

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaNMPA #DrugApproval #Garsorasib #NSCLC #KRASG12C #InnovativeDrug #ChiataiTianqing #LungCancer
November 7, 2025 at 8:45 AM
newsen.bsky.social
InxMed's Groundbreaking Publication on Ifebemtinib and Garsorasib in NSCLC Featured in The Lancet Respiratory Medicine#China#Nanjing#NSCLC#Ifebemtinib#Garsorasib
InxMed's Groundbreaking Publication on Ifebemtinib and Garsorasib in NSCLC Featured in The Lancet Respiratory Medicine
InxMed announces the publication of promising phase II trial results for Ifebemtinib and Garsorasib in treating NSCLC. Key efficacy data revealed.
third-news.com
July 9, 2026 at 9:35 AM
sigtrans-sttt.bsky.social
Findings from a phase II #ClinicalTrial reveal that #Garsorasib + cetuximab combination therapy shows enhanced anti-tumor activity in KRAS G12C-mutated #ColorectalCancer and promising outcomes for advanced disease management.
#OpenAccess: doi.org/10.1038/s413...
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
May 16, 2026 at 3:30 PM
sigtrans-sttt.bsky.social
Phase II trial shows #KRASG12CInhibitor #Garsorasib, alone or with #cetuximab, delivers promising efficacy and manageable safety in heavily pretreated KRAS G12C–mutated #ColorectalCancer patients. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation - Signal Transduction ...
Signal Transduction and Targeted Therapy - Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors...
doi.org
September 1, 2025 at 10:48 AM
l2plabs.bsky.social
InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation
NANJING, China, July 9, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly...
dlvr.it
July 9, 2026 at 9:32 AM
seldon-dengyue.bsky.social
5 innovadores medicamentos chinos, incluyendo inhibidores de:
🧬 KRAS G12C
🧬 EGFR de tercera generación
🧬 EGFR exon 20

#Fulzerasib #Sunvozertinib #Limertinib #Glecirasib #Garsorasib #Cáncer #Oncología #TerapiaDirigida #InnovaciónMédica #KRAS
#KRASG12C #EGFR #EGFRexon20 #DengYueMedicinasEnHongKong
March 6, 2026 at 3:56 AM